BeOne Medicines ((ONC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BeOne Medicines (ONC) has initiated a Phase 1a/1b clinical study titled Phase 1a/1b Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and Its Safety and Tolerability in Patients With Autoimmune Dermatological Diseases. The study aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGB-45035, a novel drug, in both healthy individuals and adults with autoimmune dermatological conditions such as atopic dermatitis and prurigo nodularis.
The intervention being tested is BGB-45035, an orally administered drug. It is designed to evaluate its effects across different dosing regimens and in the presence of food, with the ultimate goal of treating autoimmune dermatological diseases.
The study employs a randomized, sequential intervention model with double-blinding for certain parts and open-label for others. Its primary purpose is treatment-focused, aiming to gather comprehensive data on the drug’s effects.
The study began on March 26, 2024, with the last update submitted on September 11, 2025. The primary completion and estimated completion dates have not been specified, indicating the study is still in progress.
This update could influence BeOne Medicines’ stock performance positively, as successful results may enhance investor confidence and position the company favorably against competitors in the autoimmune treatment market. The ongoing recruitment and study progress are crucial for maintaining investor interest and potential market impact.
The study is currently recruiting, with further details accessible on the ClinicalTrials portal.